Physician profile
Waldo Acebo
NPI 1063451433
$8,005.07
in general payments reported to CMS, 2019-2025
29 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,089 · 2020: $1,365 · 2021: $1,251 · 2022: $739 · 2023: $1,080 · 2024: $1,014 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,340.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Galderma Laboratories, L.P. | $716.64 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $699.29 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $590.84 | 2019-2023 | Synjardy, Jardiance |
| Amgen INC. | $575.19 | 2023-2025 | Otezla, Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $554.22 | 2019-2025 | Zoryve, Seglentis |
| Novo Nordisk INC | $536.82 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $357.07 | 2019-2023 | |
| Amarin Pharma, INC. | $328.35 | 2019-2022 | |
| Exact Sciences Corporation | $272.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Azurity Pharmaceuticals, INC. | $265.62 | 2023-2025 | Edarbi, Edarbi, Adthyza |
| Astrazeneca Pharmaceuticals LP | $264.76 | 2019-2024 | Farxiga |
| Amneal Pharmaceuticals LLC | $263.89 | 2019-2023 | Unithroid |
| Arbor Pharmaceuticals, INC. | $201.86 | 2019-2022 | |
| Allergan, INC. | $186.36 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $141.28 | 2021-2022 | |
| Gilead Sciences, INC. | $131.03 | 2019-2021 | |
| Abbvie INC. | $119.99 | 2019-2024 | Botox |
| Ibsa Pharma INC. | $73.57 | 2022-2023 | Tirosint, Licart |
| Idorsia Pharmaceuticals US INC | $64.78 | 2023 | Quviviq |
| Alnylam Pharmaceuticals INC. | $63.51 | 2021 | |
| Acella Pharmaceuticals, LLC | $55.46 | 2023-2025 | NP Thyroid 60 |
| Vyne Pharmaceuticals INC. | $44.69 | 2020 | |
| Endo Pharmaceuticals INC. | $37.25 | 2020 | |
| Merz North America, INC. | $32.61 | 2022 | |
| Medicure Pharma INC. | $31.01 | 2021 | |
| Halozyme INC | $20.00 | 2023 | |
| Horizon Therapeutics Plc | $20.00 | 2021 | |
| Leo Pharma INC. | $15.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waldo Acebo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.